Prospective investigation of clinical, lipidological, vascular and hepatic parameters with regard to cardiovascular risk factors and primary prevention in childhood

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00031182

Enrollment

300

Registered

2023-02-06

Start date

2023-01-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

• GH therapy in pituitary insufficiency ICD10 = E23.0 • Autoimmune thyroid disease under therapy E06.3 • Hypothyroidism under therapy E03.9, E03.1 • Pubertas tarda under therapy E30.0 • Precocious puberty during therapy E30.1, E25.8, E22.8 • Allergies J30.1, J30.3, T78.1 • Heterozygous familial hypercholesterolemia, dyslipidemias E78.0 – E78.9 • Hyperlipoprotein(a)emia E78.0 • Arterial hypertension I10.0 - I10.9 • Cardiac Vitium Q24.9 , I05 • Cardiomyopathy I42 • Kawasaki disease WITHOUT persis

Interventions

Group 1: Pediatric patients < 20 years old who are being treated for a disease and do not have an explicitly increased risk of dyslipidemia, cardiovascular and hepatic diseases. Group 2: Pediatric pa

Eligibility

Sex/Gender

All

Age

0 Years to 20 Years

Inclusion criteria

Inclusion criteria: • Written consent to participate • Age at birth and < 20 years of age

Exclusion criteria

Exclusion criteria: • Age = 20 years at the start of the study • Acute illness • other chronic diseases or infections (e.g. HIV, TB) • Pregnancy • Known alcohol, drug and/or medication abuse • Parental Inability to Informed Consensus

Design outcomes

Primary

Measure	Time frame
The first expectation is that a preventive examination with identification of pathological lipid constellations in childhood allows for an improved early risk characterization with regard to cardiovascular complications. For this purpose, the analysis of the sdLDL cholesterol, the Lp(a) isoforms, apolipoprotein B, adiponectin and CK18F is included in this analysis.	—

Secondary

Measure	Time frame
Our second expectation is that in different risk groups as well as in individual different diseases, characteristic findings of the outcomes will be available early and expect that these will differ in patients with type 1 diabetes mellitus, in familial hypercholesterolemia and in cancer survivors.	—

Countries

Germany

Contacts

Public ContactUlrich Paetow

KKJM, Klinikum Goethe Universität

ulrich.paetow@kgu.de069630180400

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026